RIPK2 and neoplasm: Consistent with the in vitro cell proliferation results (Supplementary Fig. 4a), RIPK2-KO 22Rv1 xenografts had a significant but modest reduction in tumor growth rate, weight, and size, compared with control tumors (Supplementary Fig. 7).